Sponsors of the 2018 ANZSN ASM will be recognised as keen and vital supporters of the field. Profiles of the 2018 ASM sponsors are listed below. To find out more about how you can be involved visit the Sponsorship & Exhibition Opportunities page.
To become a Platinum, Gold, Silver or Bronze ANZSN Society sponsor please contact Jourdan at the secretariat firstname.lastname@example.org.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
UPDATE COURSE SPONSOR
Amgen is also the proud sponsor of the General Nephrology theme for the Nephrology and Transplantation Update Course held 8th – 9th September prior to the main ASM. View the program here.
Sanofi, a world leader in Life Science, committed to prevention and treatment of disease and to supporting populations throughout the world.
We are Sanofi, we live for life. By partnering with patients we can find new ways of helping them feel better, live longer, keep healthy and stay stronger.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Twentynine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines.
Founded in 1896, the Roche Group is headquartered in Basel, Switzerland, and is active in over 100 countries. In 2016 Roche employed more than 94,00 people worldwide and invested CHF 9.9 billion in research and development, including almost AUD 37 million in pharmaceuticals in Australia.
Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
Roche’s pharmaceutical division in Australia is dedicated to the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines. Australian patients have access to about 40 Roche medicines, and the company is the leading provider of cancer medicines in
Australia by sales.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. We have more than 60 years’ history in Australia and employ around 800 associates across our three divisions. We believe continued R&D is essential to innovation and in Australia we invest around 20M annually in local clinical trials. Our mission is to discover new ways to improve and extend people’s lives.
To find out more about Novartis in Australia visit the website:
UPDATE COURSE SPONSOR
Novartis is also the proud sponsor of the Transplantation theme for the Nephrology and Transplantation Update Course held 8th – 9th September prior to the main ASM. View the program here.